Objective To evaluate the efficacy of sulbactam-durlobactam based anti-infective therapy in patients co-infected with carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Klebsiella pneumoniae (CRKP). Methods A retrospective analysis was conducted on medical records of patients co-infected with CRAB and CRKP who received sulbactam-durlobactam treatment at West China Hospital, Sichuan University, between January 2025 and January 2026. Data collected included demographic characteristics, underlying diseases, microbiological findings, antimicrobial regimens, and clinical outcomes. Results A total of eight patients were included, with treatment failure in four. Patients who experienced treatment failure predominantly had severe underlying diseases and were immunocompromised. All CRAB isolates tested for resistance genes harbored blaOXA-23, while CRKP isolates predominantly carried blaKPC, with three isolates co-producing multiple carbapenemases. The primary treatment regimen was sulbactam-durlobactam combined with ceftazidime-avibactam. Notably, one patients developed CRKP infection during sulbactam-durlobactam therapy for CRAB infection. Conclusions The management of patients co-infected with CRAB and CRKP remains challenging and is associated with poor prognosis. A comprehensive, multimodal approach is urgently needed to reduce mortality in this population.
The epidemiology of respiratory viruses in China are complex and diverse, and viral infections are prone to secondary mucormycosis, posing serious challenges to clinical and public health. The consensu is formulated by domestic experts organized by the Center of Infectious Diseases of West China Hospital of Sichuan University, aiming to identify high-risk groups of respiratory virus infection secondary to mucormycosis, and put forward systematic prevention suggestions. The content covers four aspects: education and training, personal protection, early diagnosis and treatment, and infection control, forming 11 specific recommended measures. It also points out the prevention measures that are still controversial or lack evidence and future research directions, in order to improve the understanding of clinical medical staff, optimize prevention and control strategies, and reduce the risk of secondary mucormycosis.
This article explores the treatment principles of mucormycosis within the framework of international guidelines, systematically reviews the treatment strategies for different clinical types and special populations, as well as the application of surgical and local interventions in different types of mucormycosis, by integrating differences in host status, etiological characteristics, and infection sites of mucormycosis, and referencing the practical experience of hospitals in the Huaxi Mucormycosis Collaboration Network in the diagnosis and treatment of mucormycosis. The aim is to provide reference and guidance for clinical decision-making.